retatrutide peptide review – 6mg – Prime Lab Peptides Retatrutide Significantly Reduces Visceral Fat

The compound was well tolerated with no evidence of genotoxicity, indicating its potential as a therapeutic agent for type 2 diabetes and obesity in humans

The dose-response data broke down as follows: 1mg dose: 8.7% average weight loss at 48 weeks 4mg dose: 15.2% average weight loss at 48 weeks 8mg dose: 21.1% average weight loss at 48 weeks 12mg dose: 24.2% average weight loss at 48 weeks Placebo: 2.1% average weight loss at 48 weeks The week-by-week progression told an equally compelling story

The key difference between tirzepatide and semaglutide is that tirzepatide targets both GLP-1 and GIP

old reviews do not describe the current offering